Table 1:
Current ongoing clinical trials overview on liver cancer
| Patient | Intervention | Current Phase | Initiation date | Identifier |
|---|---|---|---|---|
| Advanced hepatocellular carcinoma | Sorafenib tosylate + vorinostat | Phase 1 | August 2010 | |
| Primary hepatic malignancy | Floxuridine + dexamethasone w/ bevacizumab | Phase 2 | May 2007 | |
| Advanced hepatocellular carcinoma | Bevacizumab + erlotinib | Phase 2 | April 2011 | |
| Advanced hepatocellular carcinoma | Leucovorin + 5-FU + oxaliplatin + sorafenib | January 2013 | ||
| Advanced hepatocellular carcinoma, non-resectable | 5-FU + cisplatin | Phase 2 | November 2016 | |
| Fibrolamellar carcinoma | -Everolimus -Letrozole + leuprolide -Everolimus + letrozole + leuprolide | Phase 2 | July 2012 | |
| Advanced/metastatic hepatocellular carcinoma | -MLN0128 -MLN0128 (RP2D) -Sorafenib | Phase 1/Phase 2 | July 2016 | |
| Hepatocellular carcinoma | -BMS-986183 -Nivolumab |
Phase 1/Phase 2 | August 2016 | |
| Advanced/non-resectable hepatocellular carcinoma | Tivozanib | Phase 1/Phase 2 | July 11, 2013 | |
| Advanced hepatocellular carcinoma | -Nivolumab + ipilimumab Sorafenib -Cabozantinib |
Phase 1/Phase 2 | September 26, 2012 | |
| Advanced hepatocellular carcinoma | Sorafenib + doxorubicin | Phase 2 | April 2013 | |
| Advanced hepatocellular carcinoma | -LY2157299 -Sorafenib -LY2157299 + sorafenib |
Phase 2 | August 2014 | |
| Hepatocellular carcinoma | -Ethiodized oil + doxorubicin | Phase 3 | August 2011 | |
| Advanced hepatocellular carcinoma | -Regorafenib | Phase 3 | May 14, 2013 | |
| Advanced hepatocellular carcinoma | Temsirolimus + sorafenib | Phase 2 | October 5, 2012 | |
| Hepatocellular carcinoma | LY2157299 + sorafenib LY2157299 + ramucirumab | Phase 2 | March 2011 | |
| Advanced hepatocellular carcinoma | Pexa-Vec + nivolumab | Phase 1/Phase 2 | July 27, 2017 | |
| Advanced hepatocellular carcinoma | Pex-Vec + sorafenib | Phase 3 | October 2015 | |
| Hepatocellular carcinoma | NBTXR3, intralesional or intra-arterial injection + SBRT | Phase 1/Phase 2 | November 2015 | NTC02721056 |
| Advanced hepatocellular carcinoma | MTL-CEBPA | Phase 1 | March 1, 2016 | NTC02716012 |